Dhanvantri Jeevan Rekha
- Market cap
- ₹ 10 Cr.
- P/E
- 17.7x
- P/B
- 0.99x
- 52-week range
- 19.53 – 30
- ROE
- 4%
- ROCE
- 4%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE
About
Dhanvantri Jeevan Rekha Limited is a healthcare provider. It provides medical and health-care services to the public at large. Dhanvantri Hospital is a unit of the Company with advanced and high-class patient care in Meerut. In addition to all general specialties, it has a range of super-specialty services, such as cardiology, gastroenterology, neurology, urology and other diagnostic services. Its cardiology services include an intensive coronary care unit; diagnostic facilities, including echo cardiography and color-doppler, transesophageal echocardiography, stress echo cardiography, carotid and peripheral doppler, treadmill testing, and Holter Monitoring; permanent pacemaker implantation, and peripheral angiography and angioplasty. Its neurology services include intensive management of brain attack (stroke), intensive management of status epileptics and serial seizures, management of peripheral nerve and muscle disease requiring ventilator support and management of comatose patients.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Dhanvantri Jeevan Rekha against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17.7 against a typical 21: cheaper than most peers (1st = cheapest).14th of 34
- Sales growth+41.6% against a typical +19.1% from a year earlier.6th of 31
- Profit growth+200% against a typical +25.2% from a year earlier.2nd of 24
- Share price, 3 months−13.5% against a typical −7.7%.23rd of 33
- Size₹ 9.7 Cr. market value against a typical ₹ 83 Cr. (1st = largest).29th of 34
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5 | 5 | 5 | 6 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 |
| Expenses | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 6 | 7 | 7 | 8 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | 0 |
| OPM % | 0.6% | 9.1% | 0.2% | 4.4% | 4.4% | 3.3% | 0.7% | 2.5% | −1.2% | 4% | 5.4% | 3.7% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | 0 | −0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | 0 |
| Tax % | 0% | 0% | −10% | 0% | 0% | 0% | 62.5% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −0 | 0 | −0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | 0 |
| EPS in Rs | −0.37 | 0.88 | −0.22 | 0.39 | 0.41 | 0.37 | 0.07 | 0.15 | −0.34 | 0.41 | 0.73 | 0.44 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 11%
- 5 Years
- 21%
- 3 Years
- 14%
- TTM
- 25%
- 10 Years
- −8%
- 5 Years
- 18%
- 3 Years
- 56%
- TTM
- 24%
- 10 Years
- 0%
- 5 Years
- 21%
- 3 Years
- 28%
- TTM
- —
- 10 Years
- 1%
- 5 Years
- 3%
- 3 Years
- 4%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Dhanvantri Jeevan Rekha | ₹ 22.00 | ₹ 10 Cr. | 17.7x | 1x | 4% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 63.8x | 13.2x | — | 8.1% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 67.2x | 9.3x | — | 16.7% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 62.1x | 6.6x | — | 11.3% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 92.7x | 8.4x | — | 7.4% |
| Global Health | ₹ 1,165.00 | ₹ 31,449 Cr. | 67.9x | 9.5x | — | 11.8% |
Management
- Bikram Singh
- Chief Financial Officer
- Ritika Bhandari
- Company Secretary, Compliance Officer
- Shalini Sharma
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.